Atlas Trials

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

Clinical trial NCT02388490 · COMPLETED

Trial details

NCT number
NCT02388490
Sponsor
Seoul National University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Start date
2016-03-25
Primary completion
2019-04-02
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.